http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102872054-B
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ac31afbea1cbbb03498644721ffb4a62 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-58 |
| filingDate | 2012-10-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2013-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_90dd0196e1bf2c64c8fcbe74cef0b29c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c743184ad2c5bec8f25fab02ca247776 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_719b0310d7da41ad2fcd37b6576318a2 |
| publicationDate | 2013-07-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-102872054-B |
| titleOfInvention | Application of gypensapogenin A in preparing medicine for pancreatic fibrosis prevention and treatment drugs |
| abstract | The invention discloses application of gypensapogenin A to preparation of pancreatic fibrosis prevention and treatment drugs. The application of gypensapogenin A to the preparation of anti-pancreatic fibrosis drugs is firstly publicized, the skeleton type is brand-new, the pancreatic fibrosis suppression activity is unexpectedly strong and the possibility of giving any revelation by other compounds does not exist, so that prominent substantive features are provided and a remarkable progress in the prevention of the pancreatic fibrosis is made at the same time. |
| priorityDate | 2012-10-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 28.